Significant passive protective effect against anthrax by antibody to Bacillus anthracis inactivated spores that lack two virulence plasmids

Microbiology

Volumn 152, Issue 10, 2006, Pages 3103-3110

  Enkhtuya, Jargalsaikhan ^a   Kawamoto, Keiko ^a   Kobasyashi, Yoshiyasu ^a   Uchida, Ikuo ^b   Rana, Neeraj ^a   Makino, Sou Ichi ^a  

^a OBIHIRO UNIVERSITY OF AGRICULTURE AND VETERINARY MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF ANIMAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; BACILLUS ANTHRACIS IMMUNOGLOBULIN G ANTIBODY; BACTERIUM ANTIBODY; FORMALDEHYDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; BACILLUS CEREUS; BACILLUS SUBTILIS; BACILLUS THURINGIENSIS; BACTERIAL ENDOSPORE; BACTERIAL SPORE; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; COLONY FORMING UNIT S; CONTROLLED STUDY; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; IMMUNOHISTOCHEMISTRY; LETHAL DOSE; LIVER; MACROPHAGE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PLASMID; PRIORITY JOURNAL; PROTEIN TARGETING; PROVOCATION TEST; RABBIT; SPORE GERMINATION; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

ANIMALS; ANTHRAX; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; BACILLUS ANTHRACIS; BACILLUS CEREUS; BACILLUS SUBTILIS; BACILLUS THURINGIENSIS; BLOTTING, WESTERN; CELL LINE; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; LIVER; MACROPHAGES; MICE; MICE, INBRED ICR; PLASMIDS; SPLEEN; SPORES, BACTERIAL; SURVIVAL ANALYSIS; VIRULENCE;

BACILLUS ANTHRACIS; BACILLUS CEREUS; BACILLUS SUBTILIS; BACILLUS THURINGIENSIS; ORYCTOLAGUS CUNICULUS;

EID: 33749617827     PISSN: 13500872     EISSN: None     Source Type: Journal    
DOI: 10.1099/mic.0.28788-0     Document Type: Article

References (41)

1. Beedham, R. J., Turnbull, P. C. & Williamson, E. D. (2001). Passive transfer of protection against Bacillus anthracis infection in a murine model. Vaccine 19, 4409-4416.
2. Brey, R. N. (2005). Molecular basis for improved anthrax vaccines. Adv Drug Deliv Rev 57, 1266-1292.
3. Brossier, F., Levy, M. & Mock M. (2002). Anthrax spores make an essential contribution to vaccine efficacy. Infect Immun 70, 661-664.
4. Cohen, S., Mendelson, I., Altbourn, Z. & 12 other authors (2000). Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax. Infect Immun 68, 4549-4558.
5. Dixon, T. C., Fadl, A. A., Koehler, T. M., Swanson, J. A. & Hanna, P. C. (2000). Early Bacillus anthracis-macrophage interactions: intracellular survival and escape. Cell Microbiol 2, 453-463.
6. Gu, M. L., Leppla, S. H. & Klinman, D. M. (11999). Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine 17, 340-344.
7. Guidi-Rontani, C., Weber-Levy, M., Labruyere, E. & Mock M. (1999). Germination of Bacillus anthracis spores within alveolar macrophages. Mol Microbiol 31, 9-17.
8. Guidi-Rontani, C., Levy, M., Ohayon, H. & Mock M. (2001). Fate of germinated Bacillus anthracis spores in primary murine macrophages. Mol Microbiol 42, 931-938.
9. Hahn, U. K., Boehm, R. & Beyer, W. (2005). DNA vaccination against anthrax in mice - combination of anti-spore and anti-toxin components. Vaccine 24, 4569-4571.
10. Huang, C. M., Foster, K W., DeSilva, T. S., Van Kampen, K. R., Elmets, C. A. & Tang, D. C. (2004). Identification of Bacillus anthracis proteins associated with germination and early outgrowth by proteomic profiling of anthrax spores. Proteomics 4, 2653-2661.
11. Iacono-Connors, L. C., Welkos, S. L., Ivins, B. E. & Drarymple, J. M. (1991). Protection against anthrax with recombinant virus-expressed protective antigen in experimental animals. Infect Immun 59, 1961-1965.
12. Inglesby, T. V., O'Toole, T., Henderson, D. A. & 14 authors (2002). Anthrax as biological weapon. JAMA 287, 2236-2252.
13. Jernigan, J. A., Stephens, D. S., Ashford, D. A. & 20 other authors (2001). Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 7, 933-944.
14. Jernigan, D. B., Raghunathan, P. L., Bell, B. P. & 32 other authors (2002). Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 8, 1019-1028.
15. Joyce, J., Cook J., Chabot, D. & 11 other authors (2006). Immunogenicity and protective efficacy of Bacillus anthracis polyy-γ-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy. J Biol Chem 281, 4831-4843.
16. Kim, H. S., Sherman, D., Johnson, F. & Aronson, A. I. (2004). Characterization of a major Bacillus anthracis spore coat protein and its role in spore inactivation. J Bacteriol 186, 2413-2417.
17. Kobiler, D., Gozes, Y., Rosenberg, H., Marcus, D., Reuveny, S. & Altbourn, Z. (2002). Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect Immun 70, 544-560.
18. Kudva, I. T., Griffin, R. W., Garren, J. M., Calderwood, S. B. & John, M. (2005). Identification of a protein subset of the anthrax spore immunome in humans immunized with the anthrax vaccine adsorbed preparation. Infect Immun 73, 5685-5696.
19. Little, S. F. & Knudson, G. B. (1986). Comparative efficacy of Bacillus anthracis live spore vaccine 'and protedive antigen vaccine against anthrax in the guinea pig. Infect Immun 52, 509-512.
20. 2-dependent expression of the genetic region for encapsulation from Bacillus anthracis. Mol Microbiol 2, 371-376.
21. Mendelson, I., Gat, O., Aloni-Grinstein, R. & 7 other authors (2005). Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components. Vaccine 23, 5688-5697.
22. Mikesell, P. B., Ivins, B. E., Ristroph, J. D. & Dreier, T. M. (1983). Evidence for plasmid-mediated toxin production in Bacillus anthracis. Infect Immun 39, 371-376.
23. Mock, M. & Fouet, A. (2001). Anthrax. Annu Rev Microbiol 55, 647-671.
24. Nourez, M., Lacy, D. B., Cunningham, K., Legmann, R., Sellman, B. R., Mogridge, J. & Collier, R. J. (2002). 2001: a year of major advances in anthrax toxin research. Trends Microbiol 10, 287-293.
25. Okinaka, R. T., Cloud, K., Hampton, O. & 11 other authors (1999a). Sequence, assembly and analysis of pXO1 and pXO2. J Appl Microbiol 87, 261-262.
26. Okinaka, R. T., Cloud, K, Hampton, O. & 12 other authors (1999b). Sequence and organization of pXO1, the large Bacillus anthracis plasmid harboring the anthrax toxin genes. J Bacteriol 181, 6509-6515.
27. Pitt M. L., Little, S. F., Ivins, B. E., Fellows, P., Barth, J., Hewetson, J., Gibbs, P., Dertzbaugh, M. & Friedlander, A. M. (2001). In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19, 4768-4773.
28. Ramirez, D. M., Leppla, S. H., Schneerson, R. & Shiloach, J. (2002). Production, recovery and immunogenicity of the protective antigen from a recombinant strain of Bacillus anthracis. J Ind Microbiol Biotechnol 28, 232-238.
29. Read, T. D., Salzberg, S. L., Pop, M. & 10 other authors (2002). Comparative genome sequencing for discovery of novel polymorphisms in Bacillus anthracis. Science 296, 2028-2033.
30. Rhie, G. E., Park, Y. M., Chun, J. H., Yoo, C. K, Seong, W. K. & Oh, H. B. (2005). Expression and secretion of the protective antigen of Bacillus anthracis in Bacillus brevis. FEMS Immunol Med Microbiol 45, 331-339.
31. Romanov, G. I. (1980). Preparation, control and application of anthrax vaccine in USSR. Arch Exp Veterinarmed 34, 119-122 (in German).
32. Steichen, C., Chen, P., Kearney, J. F. & Turnbough, C. L., Jr (2003). Identification of the immunodominant protein and other proteins of the Bacillus anthracis exosporium. J Bacteriol 185, 1903-1910.
33. Sylvestre, P., Couture-Tosi, E. & Mock, M. (2002). A collagen-like surface glycoprotein is a structural component of the Bacillus anthracis exosporium. Mol Microbiol 45, 169-178.
34. Turnbull, P. C. (1991). Anthrax vaccines: past, present and future. Vaccine 9, 533-539.
35. Turnbull, P. C. (2002). Introduction: anthrax history, disease and ecology. Anthrax 271, 1-19.
36. Uchida, I., Hashimoto, K. & Terakado, N. (1986). Virulence and immunogenicity in experimental animals of Bacillus anthracis strains harboring or lacking 110 MDa and 60 MDa plasmids. J Gen Microbiol 132, 557-559.
37. Uchida, I., Makino, S., Sasakawa, C., Yoshikawa, M., Sugimoto, C. & Terakado, N. (1993). Identification of a novel gene, dep, associated with depolymerization of the capsular polymer in Bacillus anthracis. Mol Microbiol 9, 487-496.
38. Vodka, M. H. & Leppla, S. H. (1983). Cloning of the protective antigen gene of Bacillus anthracis. Cell 34, 693-697.
39. Watson, J., Koya, V., Leppla, S. H. & Daniell, H. (2005). Expression of Bacillus anthracis, protective antigen in transgenic chloroplasts of tobacco, a non-food/feed crop. Vaccine 22, 4374-4384.
40. Welkos, S. L. & Friedlander, A. M. (1988). Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb Pathog 5, 127-139.
41. Williamson, E. D., Hodgson, I., Walker, N. J. & 9 other authors (2005). Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax. Infect Immun 73, 5978-5987.